SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...
The Leukemia & Lymphoma Society's Scenic Shore Bike Tour Offers a Unique Ride Experience to Help Advance Lifesaving Research, Support, and Advocacy
WASHINGTON, July 2,...
"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era"
BOSTON,...
Every year in B.C., approximately 130 children are diagnosed with cancer. As the province's only full-service acute-care hospital dedicated to children, BC Children's Hospital...
As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease.
AURORA, Colo.,...
Study is the first to explore the impact of genetic ancestry on tumor genomics in T-ALL
PHILADELPHIA and MEMPHIS, Tenn., June 24, 2025 /PRNewswire/ --...
En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie1
LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...